204 related articles for article (PubMed ID: 1386904)
1. Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients.
Dentico P; Volpe A; Buongiorno R; Maracchione N; Carbone M; Manno C; Proscia F
Nephron; 1992; 61(3):324-5. PubMed ID: 1386904
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B vaccination in dialysis centres: advantages and limits.
Rapicetta M
Nephron; 1992; 61(3):284-6. PubMed ID: 1386901
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up.
Docci D; Cipolloni PA; Mengozzi S; Baldrati L; Capponcini C; Feletti C
Nephron; 1992; 61(3):352-3. PubMed ID: 1386909
[TBL] [Abstract][Full Text] [Related]
4. Immune response after vaccination with recombinant hepatitis surface antigen in maintenance hemodialysis patients and healthy controls.
Allegra V; Vasile A; Maschio M; Mengozzi G
Nephron; 1992; 61(3):339-40. PubMed ID: 1386908
[TBL] [Abstract][Full Text] [Related]
5. Immunization and vaccination protocol in hemodialysis patients with naturally acquired hepatitis B antibody.
Faranna P; Cozzi G; Belloni M; Pedrini L
Nephron; 1992; 61(3):311-2. PubMed ID: 1386903
[TBL] [Abstract][Full Text] [Related]
6. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
Gunn TR; Bosley A; Woodfield DG
N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention: HBV vaccination in hemodialysis unit.
Sapio C; Bonifati A; Confessore A; Gatti M; Maimone I; Minella MP; Scarpino L; D'Alessandro C
Nephron; 1992; 61(3):360-1. PubMed ID: 1386911
[TBL] [Abstract][Full Text] [Related]
9. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients.
Bruguera M; Rodicio JL; Alcazar JM; Oliver A; Del Rio G; Esteban-Mur R
Vaccine; 1990 Mar; 8 Suppl():S47-9; discussion S60-2. PubMed ID: 2139283
[TBL] [Abstract][Full Text] [Related]
10. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine.
Just M; Berger R; Scheiermann N
Vaccine; 1988 Oct; 6(5):401-2. PubMed ID: 2973694
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, antibody persistence, and safety of the 60 μg hepatitis B vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial.
Feng Y; Shi X; Shi J; Gao L; Liu G; Cheng Y; Pan M; Li C; Wang J; Guo X; Zhang Y; Liang X; Wang S
Expert Rev Vaccines; 2017 Oct; 16(10):1045-1052. PubMed ID: 28803502
[TBL] [Abstract][Full Text] [Related]
13. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients.
Ono K; Kashiwagi S
Nephron; 1991; 58(1):47-51. PubMed ID: 1830374
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects.
Ristola MA; Vuola JM; Valle M; von Reyn CF
Vaccine; 2004 Nov; 23(2):205-9. PubMed ID: 15531038
[TBL] [Abstract][Full Text] [Related]
15. [Recombinant hepatitis B vaccine in health personnel. Immunogenicity of a rapid vaccination schedule].
Cremades M; Bas J; Mayor A; Laguna P; Sanjosé L; Bruguera M
Med Clin (Barc); 1989 Dec; 93(18):684-6. PubMed ID: 2532693
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness and tolerance of genetically engineered vaccines for hepatitis B--a comparative study].
Schmid K; Strebl H; Heck KJ; Weltle D; Raithel HJ
Gesundheitswesen; 1992 May; 54(5):219-22. PubMed ID: 1535816
[TBL] [Abstract][Full Text] [Related]
17. Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B--United States, 1990-1991.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1991 Aug; 40(33):569-72. PubMed ID: 1830921
[TBL] [Abstract][Full Text] [Related]
18. Comparison of results of recombinant and plasma-derived hepatitis B vaccines in Japanese nursery-school children.
Hayashi J; Kashiwagi S; Kajiyama W; Ikematsu H; Noguchi A; Nomura H; Ikeda K
J Infect; 1988 Jul; 17(1):49-55. PubMed ID: 2974467
[TBL] [Abstract][Full Text] [Related]
19. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
[TBL] [Abstract][Full Text] [Related]
20. Vaccine choice and program participation rates when two hepatitis B vaccines are offered.
Harris AA; Daly-Gawenda D; Hudson EK
J Occup Med; 1991 Jul; 33(7):804-7. PubMed ID: 1832443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
